OGIVRI 150 mg, powder for concentrate for infusion bottle, 15 ml
Active ingredients: Trastuzumab
Commercialized according to BDPMANSM noticeDispensing in France: Prescription only
Powder for concentrate for infusionbottle, 15 mlintraveineuse
Supply resumed
Package details
Original BDPM fields are shown in French.
- Official name
- OGIVRI 150 mg, poudre pour solution à diluer pour perfusion
- Pharmaceutical form
- poudre pour solution à diluer pour perfusion
- Route of administration
- intraveineuse
- Presentation description
- 1 flacon(s) en verre de 15 ml
- Marketing authorisation holder
- BIOSIMILAR COLLABORATIONS IRELAND (IRLANDE)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 23 Apr 2019
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
60990496CIP75506082CIP133400955060826Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| TRASTUZUMABpoudre | 150 mg · un flacon | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.